12:00 AM
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Abiraterone acetate: Phase I/II started

Cougar began an open-label, dose-escalation, U.K. Phase I/II trial in 74 female patients with advanced, estrogen receptor- or androgen receptor-positive, metastatic breast cancer that has progressed after >=2 hormonal therapies. Cougar received exclusive,...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >